The use of platelet rich plasma (PRP) has been proposed for tendon and ligament healing, because platelets release growth factors and cytokine/chemokines which aid the regeneration of the tissues. We applied PRP in tendinopathies of professional athletes and we measured, from the time of PRP application until 24 hours later, a series of cytokines and growth factors in serum obtained from peripheral blood in five male subjects for studying possible systemic effect of the therapy. We did not observe modifications of these parameters: interleukin 4, interleukin 6, interleukin 10, interleukin 1a, interleukin 1b, tumor necrosis factor a (TNFa) and interferon g. We observed modifications of vascular endothelial growth factor (VEGF), endothelial growth factor (EGF), and chemokine (C-C motif) ligand 2 (CCL2).

Could platelet rich plasma have effects on systemic circulating growth factors and cytokine release in orthopaedic applications? / G. Banfi, M.M. Corsi, P. Volpi. - In: BRITISH JOURNAL OF SPORTS MEDICINE. - ISSN 0306-3674. - 40:10(2006 Oct), pp. 816-816.

Could platelet rich plasma have effects on systemic circulating growth factors and cytokine release in orthopaedic applications?

G. Banfi
Primo
;
M.M. Corsi
Secondo
;
2006

Abstract

The use of platelet rich plasma (PRP) has been proposed for tendon and ligament healing, because platelets release growth factors and cytokine/chemokines which aid the regeneration of the tissues. We applied PRP in tendinopathies of professional athletes and we measured, from the time of PRP application until 24 hours later, a series of cytokines and growth factors in serum obtained from peripheral blood in five male subjects for studying possible systemic effect of the therapy. We did not observe modifications of these parameters: interleukin 4, interleukin 6, interleukin 10, interleukin 1a, interleukin 1b, tumor necrosis factor a (TNFa) and interferon g. We observed modifications of vascular endothelial growth factor (VEGF), endothelial growth factor (EGF), and chemokine (C-C motif) ligand 2 (CCL2).
Settore MED/05 - Patologia Clinica
ott-2006
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/34924
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 34
social impact